CAMBRIDGE, Mass.--(BUSINESS WIRE)--Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has been chosen by AlwaysOn as one of the OnDC Top 100 Winners. Inclusion in the OnDC 100 signifies major developments in the creation of new business opportunities that contribute to the renewed and continued prosperity of our country. Constellation Pharmaceuticals was specially selected by the AlwaysOn editorial team and industry experts spanning the globe based on a set of five criteria: innovation, market potential, commercialization, stakeholder value, and media buzz.
